You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • 702 TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumor-dependent immune response without dose-limiting toxicity in preclinical studies

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Immune-Stimulants and Immune Modulators
702 TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumor-dependent immune response without dose-limiting toxicity in preclinical studies
Free

 

Online download statistics by month:

Online download statistics by month: November 2021 to April 2023

AbstractFullPdf
Nov 2021302022
Dec 2021114012
Jan 2022128017
Feb 202286016
Mar 2022230012
Apr 2022140025
May 202292025
Jun 202280023
Jul 202298015
Aug 20226606
Sep 202270014
Oct 202270013
Nov 2022154012
Dec 202220608
Jan 2023168015
Feb 2023194014
Mar 2023226023
Apr 2023303013
Total27270285